Interpretation of expert recommendation on diagnosis and treatment of anti-tuberculosis drug-induced liver injury

Diagnosis and treatment of anti-tuberculosis drug-induced liver injury

Authors

  • Feng Li Department of Tuberculosis, Shanghai Public Health Clinical Center, Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
  • Shuihua Lu Department of Tuberculosis, Shanghai Public Health Clinical Center, Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China

References

Chinese Society for Tuberculosis. Expert recommendation on diagnosis and treatment of anti-tuberculosis drug induced liver injury. Chin J Tuberc Respir Dis 2013;36:732-6.

Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One 2011;6:e21836.

Hu XN, Bao ZJ. Epidemiology of drug-induced liver injury. Zhonghua Gan Zang Bing Za Zhi 2011;19:78-80.

Li F, Lu S. Anti-tuberculosis drug induced liver injury. Chin J Clin 2014;8:4173-6.

Dai WJ, Lai RT, Wang H, et al. The analysis of clinical features and risk factors in 113 patients with drug-induced liver injury. J Clin Hepatol 2012;28:1058-65.

Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales. Hepatol Res 2004;30:148-54.

Mitchell JR, Long MW, Thorgeirsson UP, Jollow DJ. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest 1975;68:181-90.

Xu Z, Li Y, Xu J. Clinical research on adaptative hepatic injury due to anti-tuberculosis drugs. Chin J Hepatol 2013;21:697-700.

Xiao H. Risks and benefits of preventive treatment for hepatoprotection during anti-tuberculosis therapy. Chin J Tuberc Respir Dis 2013;36:722-3.

Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010;22:1235-8.

Huang AJ, Xia YY, et al. Effectiveness and safety of preventive treatment with hepatoprotective drugs during anti-tuberculosis therapy: A systematic review of clinical trials in China. Chin J Epidemiol 2010;31:826-7.

Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of anti-tuberculosis drugs after development of anti-tuberculosis treatment induced hepatotoxicity. Clin Infect Dis 2010;50:833-9.

Downloads

Published

2015-12-24

How to Cite

1.
Li F, Lu S. Interpretation of expert recommendation on diagnosis and treatment of anti-tuberculosis drug-induced liver injury: Diagnosis and treatment of anti-tuberculosis drug-induced liver injury. Community Acquir Infect. 2015;2. Accessed May 3, 2025. https://www.hksmp.com/journals/cai/article/view/252

Issue

Vol. 2 (2015)

Section

Guideline Interpretation

Downloads

Download data is not yet available.

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.